Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer
Uromonitor represents a reliable tool in the detection of NMIBC recurrence in patients undergoing routine surveillance, regardless of stage and grade. To our knowledge, this is the largest single-center study assessing Uromonitor's performance, thus validating its usefulness in clinical practice.
Authors
- Pedro Ramos (ORCID: https://orcid.org/0000-0003-2172-7439)
- Carlos Silva (ORCID: https://orcid.org/0000-0002-1549-6833)
- João Brás (ORCID: https://orcid.org/0000-0003-1867-0486)
- Francisco Botelho (ORCID: https://orcid.org/0000-0002-6666-0883)
- Luís Pacheco‐Figueiredo (ORCID: https://orcid.org/0000-0002-0581-3663)
- Mafalda Bessa‐Gonçalves (ORCID: https://orcid.org/0000-0002-0364-5168)
- Carolina Dias (ORCID: https://orcid.org/0000-0003-2884-0055)
- Carlos Silva
Institutions
- Universidade do Porto (PT)
- Hospital de São João (PT)
- IPO Porto (PT)
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto (PT)
- University of Minho (PT)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1097/ju.0000000000004335
- Citations
- 7
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01